The FDA on November 10, 2015 approved COTELLICĀ® Tablets for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with Vemurafenib. COTELLICĀ® is not indicated for treatment of patients with wild-type BRAF melanoma. COTELLICĀ® is a product of Genentech, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
